Abbott Labs (ABT) Offering Possible 16.82% Return Over the Next 14 Calendar Days

Abbott Labs's most recent trend suggests a bearish bias. One trading opportunity on Abbott Labs is a Bear Call Spread using a strike $117.00 short call and a strike $122.00 long call offers a potential 16.82% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $117.00 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $4.28 would be incurred if the stock rose above the $122.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Abbott Labs is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Abbott Labs is bearish.

The RSI indicator is at 43.2 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Abbott Labs

Better Dividend King: Johnson & Johnson vs. Abbott Laboratories
Thu, 05 May 2022 11:42:00 +0000
Dividend Kings are stocks that have increased their payouts for 50 years or longer. Although they don't always provide investors with the highest yields, you're likely to see your dividend income rise from holding these types of investments over the years. A couple of Dividend Kings you won't have to worry about paying low payouts today are Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT).

Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Wed, 04 May 2022 13:00:00 +0000
Abbott (NYSE: ABT) announced today it has received FDA clearance for its Alinity™ m STI Assay. The test simultaneously detects and differentiates four common sexually transmitted infections (STIs). STIs, when left untreated, can lead to severe health complications, including increased risk of getting certain cancers and infertility.3

The Grandmasters of Virus Surveillance
Mon, 02 May 2022 12:31:07 +0000
Our Pandemic Defense Coalition supports infectious disease research through Virus Hunter mentorships for epidemiologists.

UPDATE 1-Abbott to release some nutrition products halted after baby formula recall
Fri, 29 Apr 2022 21:41:21 +0000
Abbott Laboratories said on Friday it would release limited quantities of nutrition products that had been put on hold following a recall of some powdered infant formulas from its Michigan facility. The company had in February recalled some baby formulas, including certain Similac products, made at its plant in Sturgis after complaints about bacterial infections in infants who consumed the products. That weighed on sales at its nutrition unit in the latest reported quarter and led the company to lower its sales growth view for the full-year.

Abbott to Release Metabolic Nutrition Formulas
Fri, 29 Apr 2022 20:35:00 +0000
At the request of the U.S. Food and Drug Administration (FDA), Abbott (NYSE: ABT) is releasing limited quantities of metabolic nutrition formulas that were previously on hold following Abbott's recall of some powder infant formulas from its Sturgis, Mich., facility. The products have been tested and comply with all product release requirements before distribution. The lots being released were not included in the recall.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.